OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
ID: 351451Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$250K - $250K

Eligible Applicants

Unrestricted

Funding Category

Consumer Protection

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Dec 12, 2023 12:00 AM
  4. 4
    Due Not available
Description

The Food and Drug Administration (FDA) is offering a funding opportunity for expanding education on skin lightening products. This grant aims to advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners to raise awareness about potential risks from skin lightening products containing hydroquinone and/or mercury. The funding opportunity seeks innovative and community-based strategies and activities to strengthen the science base for education and public health awareness on the use of over-the-counter (OTC) skin lightening products. The grant amount is set at $250,000, with no cost sharing or matching requirement. The opportunity is forecasted for the fiscal year 2024 and is open to unrestricted applicants. For more information, interested parties can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or 240-402-7610.

Point(s) of Contact
Files
No associated files provided.
Similar Opportunities
FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
Food and Drug Administration
The Food and Drug Administration (FDA) is offering the FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed. This grant aims to fund innovative research that will strengthen and advance minority health and health equity objectives. The funding opportunity is focused on enhancing equity in clinical trials, increasing data available on diverse groups, and understanding diverse patient perspectives, preferences, and unmet needs. The grant has an award ceiling of $1,000,000 and an award floor of $250,000. It is expected that four awards will be granted. The deadline for application submission is December 8, 2023. For more information, contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or 240-402-7610.
Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)". This grant falls under the category of Consumer Protection and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this funding opportunity is to support research and development in non-invasive technologies, specifically quantitative tomography-based methods, to evaluate the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The funded work aims to develop an accurate, sensitive, and reproducible approach to measure the amount of drug present in the skin at various depths below the surface. This approach will be used to monitor the cutaneous pharmacokinetics (PK) of the drug over time. The ultimate goal is to develop a scientifically valid in vivo cutaneous PK-based approach that can efficiently demonstrate the bioequivalence (BE) of topical products. The grant has an award ceiling and floor of $250,000, and it is expected that one award will be made. The eligibility for this grant is unrestricted, meaning any applicant organization can apply. However, each application must be scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. For more information or to apply for this grant opportunity, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or by phone at 240-338-7494. The deadline for this grant is forecasted to be in the fiscal year 2024.
Collaborations to Enhance Drug Development and Regulatory Science
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "Collaborations to Enhance Drug Development and Regulatory Science". This grant aims to support, manage, and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. The FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation by supporting efforts to accelerate drug product development, approaches to advanced manufacturing, translation of basic science discoveries into therapeutics, and approaches to enhance the safety, efficacy, quality, and performance of drug products. The grant has an award ceiling and floor of $5,000,000 and expects to fund 6 awards. The grant is forecasted and falls under the category of funding activity for Consumer Protection. The grant is open to unrestricted eligible applicants. The deadline for application submission is in the fiscal year 2024. For more information, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610.
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required". This grant aims to fund clinical trials of products that evaluate efficacy and/or safety in order to support a new indication or change in labeling to address unmet needs in rare diseases or conditions. The FDA expects that by funding collaborative, efficient, and/or innovative clinical trials, the number of approved treatments for rare diseases will increase, thereby having a positive impact on rare disease drug development. The grant does not require cost sharing or matching and falls under the category of Science and Technology and other Research and Development. The grant has a closing date of September 22, 2024, and the award ceiling is $650,000, with a minimum award floor of $200,000. It is expected that 20 awards will be granted. Eligible applicants include various types of organizations such as higher education institutions, nonprofits, for-profit organizations, governments, and foreign institutions. For more information, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-23-001.html). For any inquiries, the grantor contact is Shashi Malhotra, a Grants Management Specialist, who can be reached at shashi.malhotra@fda.hhs.gov or by phone at 2404027592.
Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
Food and Drug Administration
The Food and Drug Administration (FDA) is announcing a Funding Opportunity Announcement (FOA) for a Cooperative Agreement titled "Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)". This opportunity falls under the category of Food and Nutrition. The aim of this grant is to improve the safety of human drugs with potential nitrosamine impurity liabilities. The FDA is seeking proposals to conduct research, development, and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The grant recipient will also assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends. The grant amount for this opportunity is set at $350,000, with an expected number of awards being 1. There is no cost sharing or matching requirement for applicants. The eligible applicants are unrestricted, meaning any organization can apply. However, applicant organizations may submit more than one application, provided that each application is scientifically distinct. For more information and to apply, interested parties can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The deadline for submission is November 30, 2023.